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A phase I trial of the selective oral cyclin-dependent kinase
inhibitor seliciclib (CYC202; R-Roscovitine), administered twice
daily for 7 days every 21 days
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Seliciclib (CYC202; R-roscovitine) is the first selective, orally bioavailable inhibitor of cyclin-dependent kinases 1, 2, 7 and 9 to enter
clinical trial. Preclinical studies showed antitumour activity in a broad range of human tumour xenografts. A phase I trial was
performed with a 7-day b.i.d. p.o. schedule. Twenty-one patients (median age 62 years, range: 39–73 years) were treated with doses
of 100, 200 and 800 b.i.d. Dose-limiting toxicities were seen at 800 mg b.i.d.; grade 3 fatigue, grade 3 skin rash, grade 3 hyponatraemia
and grade 4 hypokalaemia. Other toxicities included reversible raised creatinine (grade 2), reversible grade 3 abnormal liver function
and grade 2 emesis. An 800 mg portion was investigated further in 12 patients, three of whom had MAG3 renograms. One patient
with a rapid increase in creatinine on day 3 had a reversible fall in renal perfusion, with full recovery by day 14, and no changes
suggestive of renal tubular damage. Further dose escalation was precluded by hypokalaemia. Seliciclib reached peak plasma
concentrations between 1 and 4 h and elimination half-life was 2–5 h. Inhibition of retinoblastoma protein phosphorylation was not
demonstrated in peripheral blood mononuclear cells. No objective tumour responses were noted, but disease stabilisation was
recorded in eight patients; this lasted for a total of six courses (18 weeks) in a patient with ovarian cancer.
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The cyclin-dependent kinases (Cdks) have been reported to play
critically important roles in several key cellular processes that are
frequently dysregulated in cancer, including cell cycling, transcrip-
tion and apoptosis (Malumbres and Barbacid, 2001; Benson et al,
2005). The design of small molecule inhibitors of Cdks has,
therefore, been actively pursued, and a considerable number of
small molecule inhibitors of these serine–threonine kinases have
been identified. The first compounds in this class to be evaluated
in clinical trials were flavopiridol and the 7-hydroxy derivative of
staurosporine, UCN-01 (Senderowicz et al, 1998; Sausville et al,
2001). These first-generation Cdk inhibitors lacked specificity,
being broad-spectrum inhibitors that inhibited not only the Cdks
but also many other kinases. Second-generation inhibitors were
designed to be more selective, with many of these compounds
specifically developed to target selected Cdks (Meijer and
Raymond, 2003). Seliciclib (CYC202; R-roscovitine) is a 2,6,9-
tri-substituted purine analogue of olomoucine derived from
studies evaluating the structure– activity relationships within this
compound class (Meijer et al, 1997; Gray et al, 1998; McClue et al,
2002; Whittaker et al, 2004). The co-crystal structure of seliciclib
and Cdk2 has been described, with the drug occupying the
ATP-binding pocket of the kinase (De Azevedo et al, 1997).
Seliciclib is a highly selective, orally bioavailable, small molecule
inhibitor of several Cdks, competing at their ATP-binding sites
(Meijer et al, 1997). It is a potent inhibitor of the human Cdk2/
cyclin E, Cdk1/cyclin B, Cdk7/cyclin H and Cdk9/cyclin T1 with
IC50s of 0.1, 2.7, 0.5 and 0.8 mM, respectively (McClue et al, 2002). It
is, however, only a weak inhibitor of Cdk4, Cdk6 and Cdk8. In a
148 kinase screen, seliciclib was highly Cdk specific, with few other
enzymes being inhibited only at micromolar concentrations (Bach
et al, 2005). The latter includes CaM kinase 2, CK1a, CK1d,
DYRK1A, EPHB2, ERK1, ERK2, FAK and IRAK4. The other
kinases tested were insensitive to seliciclib. This screen was not,
however, exhaustive, testing only approximately 30% of known
kinases. Affinity purification of proteins bound to R-roscovitine-
agarose beads also identified pyridoxal kinase (PDXK) as a target
of seliciclib, binding not at the ATP-binding site but at the
pyridoxal site (Tang et al, 2005). Pyridoxal kinase (PDXK)
catalyses the phosphorylation of pyridoxine, pyridoxal and
pyridoxamine to, respectively pyridoxine-50-phosphate, pyridoxal-
50-phosphate and pyridoxamine-50-phosphate respectively.
Seliciclib has antitumour activity against a broad range of cancer
cell lines (McClue et al, 2002; Whittaker et al, 2004; Raynaud et al,
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2005). Molecular pharmacology studies in human colorectal cancer
cell lines have revealed that seliciclib decreases retinoblastoma
protein phosphorylation, initially at the Cdk2 phosphorylation site
and then at multiple sites (Whittaker et al, 2004). Seliciclib also
causes increases in Erk-1 and Erk-2 phosphorylation, although this
may have little impact on cell cycling (Whittaker et al, 2004). More
importantly, through its inhibitory effects on Cdk7 and Cdk9,
seliciclib inhibits RNA polymerase II phosphorylation and total
RNA polymerase II protein activity (Whittaker et al, 2004;
Raynaud et al, 2005). This results in the decreased expression of
several cyclins, including cyclins D1, A and B1, which may explain
the observed global effects on retinoblastoma (RB) phosphoryla-
tion and the overall cell cycle effects of seliciclib in these models.
These include a decreased proportion of cells in G1, decreased
DNA synthesis in the S-phase and a moderate increase in cells in
G2/M (Whittaker et al, 2004; Raynaud et al, 2005).
Other studies report that this agent also blocks the degradation
of p53 through the inhibition of MDM2 expression (Lu et al, 2001).
Studies in the Lovo colorectal carcinoma cell line indicate that
the major effect on these cells is the induction of cell death from
all compartments of the cell cycle (Schutte et al, 1997; McClue et al,
2002). The antitumour efficacy of seliciclib has been demonstrated
in human tumour xenografts in nude mice, when administered
at 500 mg kg1 twice a day or 200 mg kg1 thrice a day (McClue
et al, 2002; Raynaud et al, 2005). Pharmacokinetic –pharmaco-
dynamic relationships were established in the HCT116 human
colon cancer xenograft model and showed reduced phosphoryla-
tion of RB and decreased expression of cyclin D1 in tumour
tissue (Raynaud et al, 2005). Seliciclib was most active in inhibiting
the proliferation of colon, non-small-cell lung, breast and
prostate human cancer xenografts. It also induces caspase-
dependent apoptosis in primary B-cell chronic lymphatic leukaemia
cells ex vivo, downregulating the antiapoptotic proteins Mcl-1
and XIAP, and increasing Bak expression and Bax cleavage (Alvi
et al, 2005). In addition, seliciclib demonstrates antitumour
activity in multiple myeloma cultures and cell lines, inducing
apoptosis associated with downregulation of Mcl-1 and interleukin
(IL)-6 transcription and protein expression (MacCallum et al,
2005; Raje et al, 2005).
Seliciclib has a satisfactory preclinical pharmacokinetic (PK)
profile and is extensively cleared into inactive metabolites, with the
carboxylate being the main urinary metabolite after administration
to mice and following incubation with hepatic microsomes (Nutley
et al, 2005). Seliciclib demonstrated a higher area-under-the-curve
(AUC), longer elimination half-life and better intratumoral drug
delivery, when compared with the similar 2,6,9-tri-substituted
purine Cdk inhibitors olomoucine and bohemine (Raynaud et al,
2004). Seliciclib is highly bound to plasma proteins (90%),
primarily albumin (Vita et al, 2005). To characterise further the
PK of this agent, a first in-human, single oral dose, volunteer study
was undertaken in 12 healthy subjects, administering between
50 and 800 mg of seliciclib (De la Motte and Gianella-Borradori,
2004). This showed that the parent compound is satisfactorily
absorbed, undergoes first-pass metabolism, exhibits high protein
binding and is rapidly and extensively distributed into tissues. The
carboxylate was confirmed as the main metabolite with low protein
binding, limited tissue distribution and renal clearance.
In view of these promising data, seliciclib has been studied
in early clinical trials in patients with advanced cancer, utilising
several schedules to further evaluate its safety, tolerability and
PK properties. The principal objectives of this phase I trial of
seliciclib administered orally twice a day for 7 days every 21 days
were (1) to determine the toxicity profile of seliciclib (2) to identify
the dose limiting toxicities of seliciclib, (3) to establish the
recommended dose of seliciclib on this schedule, (4) to
characterise the PK behaviour of seliciclib and (5) to document
possible anticancer activity in patients with advanced solid
malignant diseases.
PATIENTS AND METHODS
Patient selection
Patients with a histologically confirmed diagnosis of a malignant
solid tumour, refractory to conventional treatment were eligible
for treatment, provided they met the following criteria: age X18
years; World Health Organization (WHO) performance statusp2;
estimated life expectancy X3 months; no previous anticancer
therapy within 4 weeks; no significant gastrointestinal disease
influencing drug absorption; adequate hematopoietic, hepatic and
renal functions (HbX9 g dl1, WBCX3.5 109 l1, neutrophils4
1.5 109 l1, plateletsX100 109 l1, bilirubip1.25 upper limit
of normal and serum aspartate aminotransferase, alanine amino-
transferase, and alkaline phosphataseo2.5 the upper limit of
normal, plasma creatinine p130 mmo l1 or calculated creatinine
clearance according to the Cockroft formula X60 ml min1). The
study was managed and monitored by the Cancer Research UK
Drug Development Office and conducted according to Good
Clinical Practice (GCP) at the Royal Marsden Hospital (Sutton)
and the Beatson Oncology Centre (Glasgow). The protocol was
reviewed by the Cancer Research UK Central Institutional Review
Board (CIRB) protocol review committee and the clinical research
ethics committees at the above centres. All patients gave written
informed consent before entry to the study.
Treatment and dose escalation
Seliciclib was supplied by Cyclacel Ltd (Dundee, UK) as 50 and
200 mg capsules, stored at room temperature. Capsules were taken
twice daily with the patient fasting 2 h before and after drug
dosing. Patients were asked to record daily the number of capsules
taken, the time of intake and also when they had last eaten.
Compliance was assessed by counting the number of capsules
returned by the patient at the end of each treatment cycle. Patients
were hospitalised for the first cycle of treatment to facilitate
toxicity monitoring and PK sampling. Thereafter, they were treated
on an outpatient basis.
The starting dose of seliciclib was selected on the basis of animal
toxicology and PK experiments and a single dose study in patients
over the dose range 50 –200 mg. A dose of 400 mg (250 mg m2)
was predicted to achieve meaningful plasma concentrations
(410 mM) based on preclinical PK data, and a single-dose human
study demonstrated that the elimination half-life was suitable for
twice daily administration, although the interindividual variability
in clearance was high (De la Motte and Gianella-Borradori, 2004).
It was therefore decided to start at 100 mg P.O. twice daily (b.i.d.)
to be administered for 7 days every 3 weeks. At least three patients
were treated at each dose level. Planned dose increments were at
least 100% until significant drug-related toxicity was observed
(grade 1 non-haematological or grade 2 neutropenia or thrombo-
cytopenia), and 40% thereafter.
Dose-limiting toxicity (DLT) was defined as drug-related
toxicity in the first cycle, including grade 4 neutropenia for 7
days or more, neutropenic fever, platelet counto25 109 l1 and/
or non-haematological toxicityXgrade 3. This definition excluded
nausea and vomiting subsequently responding to antiemetic
therapy and reversible grade 3 increases in liver transaminases.
The maximum tolerated dose (MTD) was defined as a dose below
which DLT occurred in more than 30% of the patients. Toxicities
were evaluated according to the National Cancer Institute
Common Toxicity Criteria, version 2.0.
Treatment assessment
Before commencing treatment, a complete medical history was
taken and physical examination was performed. The following
pretreatment baseline examinations were performed within 4
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weeks of starting treatment: full blood count, including white
blood cell differential; reticulocyte count, haptoglobin, prothrom-
bin time and Coombs test; serum biochemistry, including sodium,
potassium, urea, creatinine, calcium, phosphorus, creatine kinase
and isoenzymes, total protein, albumin, bilirubin (direct and total),
alkaline phosphatase (ALP), alanine aminotransferase (ALT),
aspartate aminotransferase (AST), g-glutamyl transferase (gGT),
lactate dehydrogenase and uric acid; urinalysis; pregnancy test,
electrocardiogram and a chest X-ray. Weekly evaluations included
history, physical examination, toxicity assessment according to
the CTC criteria version 2.0 and full blood count and serum
chemistries. Radiographic assessment of tumour was performed
within 3 weeks before the patient starting treatment and after every
two cycles, according to standard RECIST methodology. Patients
were taken off protocol upon disease progression, unacceptable
toxicity, investigator discretion, serious violation of protocol or at
their own request, and were followed for 28 days after the last
administration of the study drug.
Sample collection and pharmacokinetic analysis
For PK analysis, blood samples (approximately 8 ml each) were
collected in tubes with lithium heparin anticoagulant at the
following time points: pre-dose and 0.5, 1, 1.5, 2, 4, 8, 12 (pre-
second dose), 13, 14 and 24 h (pre-dose if day 2) after dosing on
both days 1 and 7 of the first cycle. The samples were then
centrifuged at 3000 r.p.m at 41C for 10 min, the plasma transferred
to 2 ml cryovials and frozen at 701C until analysis. Urine was
collected post-dosing for 24 h on the first day of seliciclib
administration, the total urine volume was recorded and an
aliquot stored at 201C for analysis. Concentrations of seliciclib
and its principal metabolites in plasma and urine were determined
according to a validated liquid chromatography –mass spectro-
metry detection method at Quintiles, UK and ACC, Germany.
Pharmacokinetic (PK) analysis was performed using the
trapezoidal method and log-linear regression. The following
parameters were determined either by calculation or observation:
the observed maximal concentration (Cmax), the time of observed
maximal concentration (Tmax), the area under the concentration–
time curve calculated by the trapezoidal rule (time 0 to last sample
with a quantifiable concentration (AUC (0tz)) and extrapolated
to infinity (AUC(0N)), the terminal rate constant, by log-linear
regression (lz) and the terminal half-life from lz. The value of
AUC(0N) was considered unreliable if the terminal area beyond
the last quantified sample was greater than 20% of the total
AUC(0N). Pharmacokinetic (PK) data analysis was carried out
using a noncompartmental analysis model with the aid of Kinetica
(Innaphase Limited, Amersham, UK).
Sample collection and pharmacodynamic studies
Preclinical studies indicated that inhibition of RB phosphorylation
in tumour could be detected at doses associated with inhibition
of tumour growth. It was not clear whether surrogate tissues would
provide a similar pharmacodynamic (PD) signal. Samples for PD
analysis were taken predose and on days 3, 5, 7 and 14 during the
first cycle of treatment with seliciclib. Whole blood was collected
from patients at selected time points into lithium– heparin
Vacutainers tubes (Vacutainer, BD, Franklin Lakes, NJ, USA).
Each tube was inverted several times to ensure thorough mixing
and then mixed with sterile 0.9% saline at a ratio of 1:1. This was
then layered over ficol (Lymphopreps Nycomed, Oslo, Norway)
and centrifuged at 1200 r.p.m. (400 g equivalent) at 181C for
30 min. The resulting mononuclear cell layer was then removed
and resuspended in 0.9% NaCl. Cell pellets were obtained by
centrifugation (600 g) and flash frozen in liquid nitrogen. Mono-
nuclear cells were then stored at 701C in labelled cryovials until
further analysis.
Pharmacodynamic analysis was based on molecular markers
developed in preclinical models, including the HCT116 human
colon tumour xenograft, namely inhibition of RB and RNA
polymerase II phosphorylation and downregulation of cyclin D1
(Whittaker et al, 2004; Raynaud et al, 2005). Cell pellets were
treated with lysis buffer (50 mM Tris–HCl, 150 mM NaCl, pH 7.5,
1% NP40, 2 mM PMSF, 10 mg ml1 aprotinin, 10 mg ml1 leupeptin,
1 mM activated sodium orthovanadate, 1 mM sodium fluoride and
10 mM b-glycerophosphate) for 30 min on ice. Samples (20– 100mg
of protein) were heat-denatured in Laemmli sample buffer (10%
glycerol, 5% b-mercaptoethanol, 2% sodium dodecyl sulphate
(SDS), 62.5 mM Tris (pH 6.8), 0.05% bromphenol blue, final
concentrations) and separated by SDS—polyacrylamide gel
electrophoresis (PAGE) using pre-cast 10 or 15-well 20 or 10%
Tris–glycine polyacrylamide gels (Invitrogen, Netherlands). All
constituents of lysis and loading buffers were obtained from Sigma
(Poole, UK) The membrane was then blocked with 0.5% casein
blocking buffer (0.5% casein hammerstein, 154 mM NaCl, 10 mM
Tris base, pH 7.6) incubated overnight with primary antibody
(phospho-RB Ser-780: Cell Signalling Technology, MA, USA); total
RB protein, sc-50, (Santa Cruz Biotechnology, CA, USA); cyclin A,
Ab 6 (Neomarkers, Fremont, CA, USA); Phospho ser5 pol II,
R2033-20, US Biological (Swampscott, MA, USA); Phospho ser2
pol II, H5 MMS-129R (Covance, Berkeley, CA, USA); total pol II,
Ab5408 (Abcam, Cambridge, UK); and GAPDH (Chemicon, CA,
USA).
Visualisation of the bound primary antibody was performed by
probing with horseradish peroxide (HRP)-conjugated secondary
antibody (anti-rabbit (Bio-Rad, CA, USA); anti-mouse (Amersham
Biosciences, Bucks, UK)). The membrane was immersed in ECL
reagent (Pierce Biotechnology, Rockford, IL, USA) for 1 min and
then exposed to photographic film (Hyperfilm, Amersham
Biosciences, Bucks, UK) and processed.
RESULTS
General
Between August 2001 and September 2003, 22 patients with
metastatic disease were enrolled from the two centres and their
demographic characteristics are listed in Table 1. All 22 patients
were eligible, but one was withdrawn before receiving treatment
owing to rapid disease and symptom progression. Patients had
received a median number of two prior chemotherapy regimens.
A total number of 42 fully assessable courses were administered.
The median number of courses per patient was 2; range 1– 6. The
following dose levels were studied: 100 mg b.i.d, 200 mg b.i.d and
800 mg b.i.d.
No significant toxicity was seen at the 100 mg dose level at which
three patients were treated. At the 200 mg dose level, one patient
with advanced colorectal cancer experienced an increase in plasma
and liver enzymes, consistent with cholestasis, which did not revert
to baseline during the period of the study. The patient’s liver
biochemistry at baseline was within normal limits but, between
days 21 and 28 grade 3 elevations of bilirubin, gGT, ALP, AST and
ALT were noted. Subsequent ultrasound investigation revealed
new liver metastases, but no features of biliary obstruction. The
changes in liver biochemistry persisted and did not revert to
baseline upon cessation of treatment, suggesting this may have
been tumour-related. The patient was consequently withdrawn
from the trial. Nonetheless, this was classified as a DLT, as it was
not transient. Three additional patients were recruited at this dose
level and no further DLT was reported. At this point, review of the
PK data obtained at the 100 and 200 mg dose levels indicated that
these doses resulted in very low drug exposure. In addition, 400 mg
twice daily for 5 days every 3 weeks appeared to be well tolerated
in another seliciclib Phase I trial ongoing at the time. A protocol
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amendment was made to dose escalate from 200 to 800 mg. At the
800 mg dose level, reversible grade 1 and 2 increases in plasma
creatinine, reversible grade 3 and 4 hypokalaemia, reversible grade
3 hyponatraemia and a grade 3 skin rash were observed, so the
cohort was expanded to six patients. No further DLTs were
experienced in the additional group of three patients. A further
protocol amendment allowed a cohort expansion of an additional
group of six patients (12 patients in total) to facilitate closer
investigation of the putative renal/biochemical toxicities of
seliciclib. Four of the final six patients treated at 800 mg
experienced seliciclib-related DLTs. In three of these patients, this
involved reversible elevations of gGT, and in one patient,
hyperglycaemia and glycosuria.
Toxicity profile
Overall haematological toxicity was mild and did not result in DLT.
Nausea was the most commonly reported adverse event and
increased in frequency with increasing dose. At the 800 mg dose
level, 11 of the 12 patients experienced nausea, although this was
not dose-limiting. This symptom was satisfactorily managed with
routine antiemetics, including 5-HT3 antagonists. Other commonly
reported drug-related adverse events included lethargy, fatigue and
anorexia. Hypokalaemia, rash and fatigue were the principal DLTs,
and were mainly observed at the 800 mg b.i.d. dose level. Further
details of these adverse events are summarised in Table 2.
Electrolyte disturbance and renal impairment
Hypokalaemia considered related to seliciclib was noted in patients
receiving 800 mg b.i.d. At this dose, hypokalaemia was observed
in five of 12 patients (o3.0 mmol l1), which was grade 1 in two
patients, grade 3 in two patients and grade 4 in one patient. This
was not deemed to be a result of nausea and vomiting or
concomitant diuretic or nephrotoxic therapy. These biochemical
changes were first observed on day 7 of seliciclib dosing, as routine
electrolyte testing was initially performed only on days 1 and 7
during the treatment period. Additional blood testing revealed
that these changes occurred as early as day 3 of treatment.
Hypokalaemia was easily reversible with potassium supplementa-
tion and was not associated with any electrocardiographic changes.
Clinically significant elevations in urea and creatinine were also
observed and were correctable with increased oral or intravenous
fluids. These biochemical changes appeared to occur separately
from the aforementioned hypokalaemia.
This toxicity can be characterised further by describing a typical
patient history. In one patient treated at 800 mg b.i.d., serum
potassium fell to 2.2 mmol l1 on day 7 of course 1, with a
creatinine level just above normal and no other identifiable cause
of hypokalaemia. This electrolyte disturbance required hospitali-
sation, for administration of intravenous and oral potassium
supplementation. This patient also developed hypokalaemia after
receiving course 2, with a nadir of 2.5 mmol l1, and on this
occasion associated with hyponatraemia (127 mmol l1) and
hypotension (82/52 mmHg) with a creatinine that was just above
the normal range (130mmol l1; normal range o110 mmol l1).
These were, however, possibly associated with concurrent poor
oral fluid intake.
At this point, the 800 mg cohort was expanded further to
investigate the possible renal effects of seliciclib. More restrictive
eligibility criteria were introduced, including a glomerular filtra-
tion rate above 60 ml min1 (estimated by 51Cr-EDTA) clearance or
24-h urine collection for creatinine clearance) and serum
potassium within normal limits. In addition, more intensive blood
chemistry testing was performed on days 1, 3, 5 and 7.
Furthermore, 24-h urine collections were obtained on days 1 and
7 and analysed for creatinine clearance, urinary electrolytes and
urine microscopy. No overall changes were seen in urinalysis, but
in one patient with hypokalaemia in this cohort, potassium
excretion in the urine was increased on day 7 compared with day 1,
suggestive of renal potassium loss.
In an attempt to understand further the pathogenesis of these
biochemical toxicities, three patients were studied more inten-
sively. Urinary retinol-binding protein (RBP), a marker of renal
tubular damage was measured in conjunction with functional renal
imaging (MAG3 renograms) to estimate renal blood flow
pretreatment on days 3 and 14. One patient experienced a rapid,
but reversible, increase in creatinine associated with a reduction in
renal perfusion bilaterally, determined by MAG3 perfusion indices.
Table 1 Patient characteristics
Gender
Male 15
Female 6
Median Age (range) years 62 (39–73)
Performance status
0 2
1 17
2 2
Site of primary disease
Colorectal 9
Ovarian 2
Unknown primary 2
Lung 1
Cervical 1
Prostate 1
Other 5
Prior treatment regimens
Chemotherapy
1 6
2 9
3 7
3+ 1
Prior hormone therapy 1
Prior radiation 8
No. of cycles of seliciclib administered 42
Median per patient 2
Range (1–6)
Table 2 Reported toxicity profile during the first course of seliciclib
treatment
Seliciclib
100 mg b.i.d
Seliciclib
200 mg b.i.d
Seliciclib
800 mg b.i.d
No. of subjects 3 6 12
No. with grade 3 & 4
adverse events
0 2 7
g GT increase 0 1 3
Hypokalemia 0 0 3
Hyperglycaemia 0 0 1
Hyponatraemia 0 0 1
Rash 0 0 1
Hypotension 0 0 1
Lymphopenia 0 0 1
Anorexia 0 0 1
Fatigue 0 0 1
ALT increased 0 1 0
AST increased 0 1 0
Alk Phos increase 0 1 0
Bilirubin increase 0 1 0
CKMB increase 0 1 0
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This was associated with bilateral increases in renal parenchymal
retention on day 3 on MAG3 scans, which reverted to normal by
day 14 (see Figure 1). By contrast, the other two patients
experienced no decline in renal function and showed no change
in MAG3 renograms. There were no consistent changes in urinary
RBP in any of these patients (Table 3).
Hyperglycaemia
Seliciclib-induced hyperglycaemia was observed in five patients
at 800 mg b.i.d., but reached grade 3 in only one patient with
associated glycosuria. This patient was not receiving concurrent
corticosteroids. The hyperglycaemia was transitory, being noted by
the end of the treatment period on day 7 and fully normalised on
cessation of drug therapy.
Other non-haematological toxicity
One patient at the 800 mg dose level experienced a grade 3 rash
occurring on day 7 of the first treatment cycle. This was
characterised by an intensely pruritic and erythematous, urticarial
rash of diffuse distribution affecting the trunk, lower limbs and
arms associated with mild systemic upset and pyrexia. The patient
was treated with topical steroid creams, emollients and anti-
histamines, and the rash resolved. The patient was subsequently
rechallenged with a second cycle of treatment and within 4 h of
the first seliciclib dose, the rash reappeared. The patient was
commenced on oral steroids and the rash again resolved within 2
weeks. Subsequent expert dermatological review confirmed that
these episodes were likely to be drug related, and were of a
vasculitic appearance. Associated biochemical abnormalities in the
same patient were also noted on day 7 of the treatment period
during both cycles 1 and 2, namely hypokalaemia, raised urea and
creatinine and hyperglycaemia. These values were within normal
limits before treatment and resolved within days of finishing
seliciclib.
Derangements in liver biochemistry, principally, elevations of
gGT and ALP were also reported during the 7-day treatment period
at both 200 mg b.i.d. (4 out of 6 patients) and 800 mg b.i.d. (10 out
of 12) dose levels. Most of the derangement was mild to moderate.
Raised liver biochemistry tests were seen by day 7 and were
reversible at the end of the course with the exception of the DLT at
the 200 mg dose level, which was probably tumour related.
Pharmacokinetics
The mean concentration vs time profile for each dose level is
shown in Figure 2. Seliciclib was absorbed relatively slowly with a
mean Tmax of 2.55 h (range 1– 4 h). The plasma clearance was
greater than liver blood flow and the terminal half-life was similar
in all dose groups (2–5 h). Table 4 summarises the pharmaco-
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Figure 1 Functional renal perfusion imaging by MAG3 nuclear scanning,
performed pretreatment (A) and post-treatment on days 3 (B) and 14
(C), in a patient who experienced a reversible decline in renal function
when treated with seliciclib at 1600 mg day1. Baseline pre-treatment
renogram (A) shows slight asymmetry in renal function with the right
kidney (dark green) slightly poorer than the left (light green). Day 3
renogram (B) shows changes consistent with bilateral parenchymal
retention and delayed intrarenal transit bilaterally, which then almost
completely recovers by day 14 (C).
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Figure 2 Concentration–time pharmacokinetic profiles (mean7
standard deviation) for all the evaluated dose levels of seliciclib (100,
200, 800 mg) on both days 1 (A) and 7 (B).
Table 3 Urinary retinol binding protein levels following treatment with
seliciclib
Urinary retinol binding protein
(0.10–100.0 mg/mol creatinine)
Patient 20 Patient 21 Patient 22
Pretreatment 8.7 136.4 6.8
Day 3 59.2 44.7 7.9
Day 14 20.8 25.7 40.1
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kinetic parameters for patients treated with seliciclib at each dose
level. Area-under-the-curve (AUC) and Cmax of seliciclib increased
with dose (Figures 3 and 4). There is a suggestion of nonlinearity,
but this is unclear from the limited data generated by this study.
There were no significant differences in the PK parameters
calculated on days 1 and 7. The ratio of the carboxylic acid
derivative which is the major metabolite (De la Motte and Gianella-
Borradori, 2004; Nutley et al, 2005) to the parent compound,
varied from 0.8 to 43 (data not shown). However, there was no
correlation between the ratio of metabolite to parent and the
plasma clearance of the parent drug. The mean Cmax at the 800 mg
dose level (3 mg ml1, 10 mM) was in the range of IC50 values
reported for seliciclib in vitro activity (McClue et al, 2002; Nutley
et al, 2005; Raynaud et al, 2005), but this concentration was
not sustained for the period required to exert an antitumour effect
in vitro.
Table 4 Summary of Seliciclib pharmacokinetics during course 1
Dose Cmax (ng ml
1) Tmax (min) t1/2 (min) AUClast (min ng ml
1) AUCinf (min ng ml
1)
Day 1 100 mg (n¼ 3) Mean 248 112 267 112236 115384
%CV 91 101 55 58 56
Median 134 61 278 82403 90289
200 mg (n¼ 6) Mean 179 279 176 165949 181877
%CV 123 95 42 62 59
Median 80 167 149 185025 230597
800 mg (n¼ 12) Mean 3197 177 219 3163604 3177921
%CV 42 68 21 43 43
Median 3161 120 232 3441798 3452569
Day 7 100 mg (n¼ 3) Mean 162 190 268 171555 173422
%CV 15 46 24 36 35
Median 152 240 234 181815 182620
200 mg (n¼ 6) Mean 310 62 781 175903 255297
%CV 43 71 173 59 89
Median 303 60 228 184620 208748
800 mg (n¼ 8) Mean 2774 99 230 1590950 1598426
%CV 71 26 43 69 69
Median 2636 107 209 1275901 1278974
A
0 200 400 600 800
0
1 000 000
2 000 000
3 000 000
4 000 000
5 000 000
0
1 000 000
2 000 000
3 000 000
4 000 000
5 000 000
6 000 000
7 000 000
Dose (mg)
0 200 400 600 800
Dose (mg)
AU
C 
(m
in 
ng
 m
l–1
)
AU
C 
(m
in 
ng
 m
l–1
)
AUC (min ng ml–1)
AUC (min ng ml–1)
B
Figure 3 Seliciclib AUC(last) values for all tested dose levels, on both
days 1 (A) and 7 (B), as a function of daily administered dose.
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Figure 4 Seliciclib Cmax values for all tested dose levels, on both days 1
(A) and 7 (B), as a function of daily administered dose.
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Pharmacodynamics
Retinoblastoma phosphorylation and cyclin D1 levels were studied
in peripheral blood mononuclear cells, compared with appropriate
controls. No reliably detectable alterations were observed. Tumour
biopsies were not obtained in this study.
Antitumour activity
No objective tumour responses were observed. One patient with
metastatic ovarian cancer, whose disease was progressing before
treatment with seliciclib, had disease stabilisation for a total of
six courses, with no change in her CA-125 tumour marker. Two of
three patients at the 100 mg b.i.d. dose level, two of six at the
200 mg b.i.d. dose level and three of 12 patients at the 800 mg b.i.d.
dose level had stable disease after course 2, but progressed by
course 4.
DISCUSSION
Cell-cycle dysregulation is a hallmark of malignancy. The Cdks
play a crucial role in controlling progression through the cell cycle,
and genetic and epigenetic mechanisms frequently result in their
deranged expression and/or activity in oncogenesis. The develop-
ment of Cdk inhibition has therefore been pursued as a potential
therapeutic strategy, although the development of selective
inhibitors of this serine–threonine kinase family has been
particularly challenging in view of the high degrees of sequence
homology between Cdks and other kinases. It has been reported
that Cdk inhibitors could inhibit tumour cell growth in preclinical
models, but many questions remain about which Cdks should be
targeted for anticancer therapy. These concerns have been fuelled
by RNA interference and knockout mice studies, indicating that
functional redundancy may exist between different Cdks, with the
loss of Cdk2 alone failing to inhibit tumour cell proliferation
(Ortega et al, 2003; Tetsu and McCormick, 2003), and the loss of
both Cdk4 and Cdk6 not preventing cell cycling (Malumbres et al,
2004). These data suggest that the optimal pharmacologic Cdk
inhibitor should selectively inhibit a broad spectrum of Cdks,
including Cdk1, 2, 4, 6, yet spare other kinases whose inhibition
results in nonspecific toxicity (Sausville, 2002).
Seliciclib is an orally bioavailable selective inhibitor of Cdk 1, 2,
7 and 9 (McClue et al, 2002; Whittaker et al, 2004). Cassette dosing
PK studies indicated that seliciclib had the most favourable PK
profile of a library of 107 different 2,6,9-tri-substituted purine
Cdk2 inhibitors, prepared by parallel synthesis (Raynaud et al,
2004). Seliciclib showed promising activity in preclinical models,
and decreased both RB and RNA Pol II phosphorylation and total
RNA Pol II protein, suggesting that in addition to Cdk2 inhibition,
it also inhibits transcription, possibly via inhibition of Cdk7 and
Cdk9 (McClue et al, 2002; Whittaker et al, 2004; MacCallum et al,
2005; Raynaud et al, 2005). Similarly, seliciclib also decreases
cyclin D1 protein levels independently of the p38SAPK and
phosphatidylinositol 3-kinase pathways and causes a reduction in
the expression of cyclins D1, A and B1, presumably by the same
mechanism. Its cell-cycle effects include a reduction of cells in G1,
inhibition of bromodeoxyuridine incorporation during S phase
and a moderate increase in G2/M phase.
We now report the clinical evaluation of the orally bioavailable
selective Cdk inhibitor seleciclib in cancer patients, using oral
dosing b.i.d. for 7 days every 3 weeks. Preclinical toxicology
studies with 28 days treatment in rodents reported anaemia,
leucocytosis, bone marrow hyperplasia, polydipsia, polyuria and
gastric ulceration. Preclinical data indicated that exposure to
seliciclib in the concentration range 7.9–30.2 mM over a 24-h
period could achieve clinically relevant biological effects (De la
Motte and Gianella-Borradori, 2004; Whittaker et al, 2004; Tang
et al, 2005). In vivo studies also indicated that a single dose of
500 mg kg1 (2750 mg m2 of mouse body surface area) achieved
levels of Z10 mM for 24 h (Raynaud et al, 2005). In men, a single
dose of 250 mg m2 (400 mg dose for a patient with a body surface
area of 1.8 m2) was predicted to achieve the same level for 4 h.
However, in a single dose bioavailability study in healthy
volunteers, considerable interindividual variability in drug ex-
posure was observed, with most of the drug being cleared by 12 h
(De la Motte and Gianella-Borradori, 2004).
In this phase I trial, no significant drug-related toxicity was
observed at the 100 or 200 mg b.i.d. dose levels, and PK data
suggested that these doses resulted in low drug exposure (see
Figure 3), hence the dose was increased to 800 mg b.i.d. for 7 days.
At this level, dose-limiting toxicities were reported comprising
reversible hypokalaemia, hyponatraemia, elevated gGT, hyper-
glycaemia and a generalised vasculitic skin rash. In addition, a
rapid rise in creatinine during the administration period was also
frequently observed. Although this did not reach grade 3 and
appeared to be reversible on stopping the drug, it was unexpected
and of concern in the absence of a clear explanation. Similar
toxicities have been reported in a separate phase I study utilising a
5-day, twice-daily administration, oral schedule (Pierga et al,
2003). In that study, vomiting, skin rash, hypokalaemia and raised
creatinine were also seen. The recommended phase II dose in that
study was 2500 mg per day for 5 days, although this was reported
to be associated with manageable grade 3 hypokalaemia and grade
3 skin rash. Preclinical toxicology had reported seliciclib-related
polyuria and polydypsia, but not renal dysfunction or hypokalaemia.
The pathogenesis of the creatinine rise is not fully understood,
but may be associated with a reversible reduction in renal blood
flow. Some evidence for this was obtained from the serial
evaluation of MAG3 isotope renograms that detected a significant,
reversible, decrease in renal blood flow in one patient, following
seliciclib therapy. The pathogenesis of this possible alteration in
renal blood flow remains unexplained. It has been proposed that
binding of seliciclib to unrelated targets such as adenosine
receptors, which regulate renal blood flow, could explain these
findings, but this has not been confirmed to date (Benson et al,
2005). The reversibility of the renal dysfunction and absence of
changes in urinary retinol-binding protein do, however, suggest
that this was not related to clinically significant tubular damage.
Although clearly distinct from the renal dysfunction, in that the
two events did not always occur simultaneously, reversible dose-
limiting hypokalemia was also observed during this study.
Whereas this was noted at the 200 mg dose level, potassium levels
below 3.0 mmol l1 were only observed at 800 mg, with potassium
levels as low as 2.2 mmol l1 in one patient. The hypokalaemia was
easily and rapidly reversible with potassium supplementation and
on discontinuation of seliciclib dosing. It was, however, thought to
be potentially dangerous and would warrant very close monitoring.
The pathogenesis of the hypokalaemia has not been elucidated.
As renal collecting duct and tubular reabsorption of potassium
(involving carbonic anhydrase) is critical to potassium homeo-
stasis, these processes may be implicated. Further studies on the
effects of seliciclib on adenosine receptors, carbonic anhydrase and
renal collecting duct and tubular function may be useful.
The pharmacokinetic data indicate that seliciclib levels were not
maintained at the level associated with antitumour activity in some
xenograft models. The mean maximum plasma concentration
achieved at the highest dose level was approximately 3 mg ml1
(10mM), whereas in the mouse, a peak seliciclib concentration of
approximately 100mM and nearly 24 h of exposure to 410 mM was
achieved with a single dose of seliciclib at 500 mg kg1 p.o. When
administered b.i.d., this resulted in significant growth delay of a
human tumour xenograft (Raynaud et al, 2005). However, the
lowest effective dose in this xenograft model was not established.
More sensitive tumours may not require such high drug levels and
it is unclear whether this discrepancy in drug exposure was
responsible for the failure to demonstrate an effect on RB
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phosphorylation and cyclin D1 in peripheral blood mononuclear
cells. A number of other factors may have contributed; for
example, peripheral blood mononuclear cells may be inappropri-
ate as a surrogate tissue for these agents in man, as they are not
actively dividing. Buccal mucosa scrapes have been used to
demonstrate changes in p53 and phospho-RB in response to
flavopiridol, although this did not translate into detectable changes
in tumour biopsies (Tan et al, 2004). In a separate study with
flavopiridol, flow cytometric studies to examine cell cycle changes
and apoptosis in peripheral blood mononuclear cells were
uninformative (Thomas et al, 2002).
Side effects such as neutropenia and gastrointestinal toxicity,
such as have been reported with other Cdk inhibitors, were not
observed during this study. It is not entirely clear what side effects
are to be expected from a broad-spectrum Cdk inhibitor, such as
seliciclib. If the biologically important effects of seliciclib are on
transcriptional regulation, it is hard to predict exactly what pattern
of side effects is likely to be observed with this agent. The
observation of seliciclib-related hyperglycaemia in five of 12
patients at the 800 mg dose level is interesting. This has been
reported with other Cdk inhibitors, possibly through inhibition of
Cdk5, which has a role in regulating insulin secretion (Sausville,
2002).
In this study DLT was observed at 800 mg, given b.i.d. for 7 days
every 21 days. Although the toxicities were reversible, they were
nevertheless of concern and it proved difficult to continue dosing
for 7 days in some patients in the presence of a consistently rising
creatinine. Plasma concentrations were not maintained above the
average IC50 concentration at this dose and schedule. However,
shorter duration regimens, that is, b.i.d. administration for 5 days,
have proved to be feasible and permit administration of higher
daily doses (Pierga et al, 2003). It was the decision of the sponsor
to pursue clinical development of the shorter duration regimen
and not to continue further investigation of the 7-day continuous
dosing regimen. Further investigations are required to explain fully
the renal side effects observed with seliciclib. An orally bioavail-
able Cdk inhibitor such as seliciclib has significant attractions. The
development of alternative PD biomarkers will assist the
identification of the optimum dose and schedule.
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